Erlotinib is a potent reversible HER1/epidermal growth factor receptor tyrosine kinase
inhibitor with single-agent activity in patients with non-small cell lung cancer. The aim of this …

Abstract Introduction The phase II JO25567 study compared the efficacy and safety of
erlotinib plus bevacizumab vs. erlotinib alone as first-line therapy for advanced epidermal …

Background Bevacizumab and erlotinib target different tumour growth pathways with little
overlap in their toxic-effect profiles. On the basis of promising results from a phase 1/2 trial …

Background: To determine the efficacy and safety of anti-angiogenic drugs combined with
erlotinib in the treatment of advanced non-small cell lung cancer (NSCLC), we performed a …

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer deaths. Erlotinib is the
first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), the …

Purpose In this phase III clinical study, we assessed the clinical outcomes of combining
erlotinib with bevacizumab and panitumumab as second-line chemotherapy for patients with …

Introduction The introduction of epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKIs) has improved the outlook for patients with advanced non-small-cell lung …

In patients with advanced non-small cell lung cancer (NSCLC), the benefit-to-risk ratio of
doublet-targeted agents versus single agent is not clear. A systematic review and …

Background In the phase II JO25567 study (JapicCTI‐111390), erlotinib plus bevacizumab
demonstrated a significant clinical benefit in Japanese patients with epidermal growth factor …

Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …